Get Updates
Get notified of breaking news, exclusive insights, and must-see stories!

Complaint against Kamal Hassan for his comment on Siddha medicine

Kamal Hassan on Wednesday took to Twitter to urge his fans not to distribute the Siddha medicine until there is proper research into it.

A complaint has been filed against actor Kamal Hassan for allegedly spreading false information about 'Nilavembu Kudineer', a herbal potion used as a treatment for dengue.

Kamal Hassan

'Nilavembu Kudineer', also called 'Nilavembu Kashayam', is a Siddha medicine recommended for prevention and management of all types of viral infections/fevers. It acts as stimulant and immunomodulator, which boosts immunity and modulates defense response in the body, which helps to protect from infections and their complications.

Kamal Hassan on Wednesday took to Twitter to urge his fans not to distribute the Siddha medicine until there is proper research into it. He tweeted stating, "It's not that the research should be done by allopathics. The traditionalists should also have done it. It is traditional for medicines to have side effects."

However, Tamil Nadu health minister C Vijayabaskar backed the use of s neem drink to fight dengue.

Answering a question on Nilavembu Kudineer, the Minister said it was a proven medicine. "Nilavembu is a proven medicine, it was tested at King Institute (a State run institution in Chennai) and it increases the platelet, it increases immunity, this has been proven," he said.

On October 13, a five-member central team deputed to assess the dengue situation in the state had termed the 40 deaths since January.

Chief Minister K Palaniswami has requested for the financial aid to Union minister Ashwini Kumar Choubey.

(With agency inputs)

Notifications
Settings
Clear Notifications
Notifications
Use the toggle to switch on notifications
  • Block for 8 hours
  • Block for 12 hours
  • Block for 24 hours
  • Don't block
Gender
Select your Gender
  • Male
  • Female
  • Others
Age
Select your Age Range
  • Under 18
  • 18 to 25
  • 26 to 35
  • 36 to 45
  • 45 to 55
  • 55+